Factors predicting mortality in invasive pneumococcal disease in adults in alberta

Medicine

Volumn 90, Issue 3, 2011, Pages 171-179

  Marrie, Thomas James ^a,e   Tyrrell, Gregory J ^b,c   Garg, Sipi ^b   Vanderkooi, Otto G ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c National Centre for Streptococcus   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CANADA; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART ARREST; HOSPITAL ADMISSION; HUMAN; INFECTION; INVASIVE PNEUMOCOCCAL DISEASE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MORTALITY; OXYGEN SUPPLY; PRIORITY JOURNAL; RISK FACTOR; STREPTOCOCCUS PNEUMONIA;

EID: 79955585019     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e31821a5a76     Document Type: Article

References (35)

1. Alanee SRJ, McGee L, Jackson D, Chiou CC, Feldman C, Morris AJ, Ortquist A, Rello J, Luna CM, Baddour LM, Ip M, Yu VL, Klugman KP. Association of serotypes of Streptococcus pneumoniae with disease severity and outcomes in adults: an international study. Clin Infect Dis. 2007;45:46-51. (Pubitemid 46984614)
2. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med. 1964;60:759-776.
3. Bruyn GAW, van der Meer JWM, Hermans J, Knoppert W. Pneumococcal bacteremia in adults over a 10-year period at University Hospital, Leiden. Rev Infect Dis. 1988;10:446-450.
4. Clothier HJ, Vu T, Sundararajan V, Andrews RM, Counahan M, Tallis GF, Lambert SB. Invasive pneumococcal disease in Victoria: a better measurement of true incidence. Epidemiol Infect. 2008;136:125-131.
5. Dwyer R, Ortqvist A, Aufwerber E, Henriques-Norman B, Marrie TJ, Mufson MA, Torres A, Woodhead MA, Aleniu M, Kalin M. Addition of a macrolide to a beta lactam antibiotic in bacteremic pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2006;25:518-521.
6. Feikin DR, Schuchat A, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance 1995-1997. Am J Public Health. 2000;90:223-229. (Pubitemid 30062674)
7. Finkelstein MS, Petkun WM, Freedman ML, Antopol SC. Pneumococcal bacteremia in adults: age-dependent differences in presentation and in outcome. J Am Geriatr Soc. 1983;31:19-27. (Pubitemid 13181066)
8. Foster D, Knox K, Walker AS, Griffiths DT, Moore H, Haworth E, Peto T, Brueggemann AB, Crook DW, Oxford Invasive Pneumococcal Surveillance Group. Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol. 2008;57:480-487. (Pubitemid 351537024)
9. Haddad MB, Porucznik CA, Joyce KE, De AK, Pavia AT, Rolfs RT, Byington CL. Risk factors for pediatric invasive pneumococcal disease in the Intermountain West, 1996-2002. Ann Epidemiol. 2008;18:139-146.
10. Harboe ZB, Thomsen RV, Riis A, Valentiner-Branth P, Christensen JJ, Lambersten L, Krogfelt DA, Konradsen HB, Benfield TL. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6(5):e1000081.
11. Hook EW, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA. 1983;249:1055-1057. (Pubitemid 13137431)
12. Johnstone J, Marrie TJ, Eurich DT, Majumadar SR. Effect of pneumococcal vaccine in hospitalized adults with community acquired pneumonia. Arch Intern Med. 2007;167:1938-1943. (Pubitemid 47606632)
13. Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG, Active Bacterial Core Surveillance Program of the Emerging Infections Program. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. Clin Infect Dis. 2005;192:372-386.
14. Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy. Crit Care Med. 2004;32:625-631. (Pubitemid 38340054)
15. Lund E, Henrichsen J. Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae. Methods Microbiol. 1978;12:242-262.
16. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med. 2009;30:210-238.
17. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia. Chest. 2005;127:1260-1270.
18. Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, Marco MA, Torres A, Mensa J. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003;36:389-395. (Pubitemid 36241302)
19. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study. Am J Med. 1999;107(Suppl 1A):34S-43S. (Pubitemid 29372759)
20. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45:158-165. (Pubitemid 47041005)
21. Pallares R, Gudiol F, Linares J, Ariza J, Rufi G, Murgui L, Dorca J, Viladrich PF. Risk factors and responses to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med. 1987;317:18-22. (Pubitemid 17093293)
22. Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney GC, Zell E, Lexau CA, Thomas AR, Harrison LH, Reingold AL, Harder JL, Farley MM, Anderson BJ, Schaffner W. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295:1668-1674.
23. Pulido M, Sorvillo F. Declining invasive pneumococcal mortality in the United States, 1990-2005. Vaccine. 2010;28:889-892.
24. Ramirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, Amir A, Moffet B, Gordon J, Blasi F, Gordon J. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47:182-187. (Pubitemid 351920618)
25. Robinson KA, Baughman W, Rothrock G, Barret NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell ER, Schuchat A, Whitney CG, for the Active Bacterial Core Surveillance Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998. Opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1725-1739.
26. Scott JAG, Hall AJ, Dagan R, Dixon JMS, Eykyn A, Fenoll M, Hortal L, Jette LD, Jorgensen JH, Lamothe F, Macfarlane JT, Shales DM, Smart LE, Taunay A. Serogroup-specific epidemiology of Streptococcus pneumonia association with age, sex and geography in 7,000 episodes of invasive disease. Clin Infect Dis. 1996;22:973-981. (Pubitemid 26260598)
27. Scott JAG. The preventable burden of pneumococcal disease in the developing world. Vaccine. 2007;25:2398-2405. (Pubitemid 46366119)
28. Sjostrum K, Spindler C, Ortqvist A, Kalin M, Sandgren A, Kuhlmann-Berenzon S, Henriques-Normark B. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis. 2006;42:451-459. (Pubitemid 43202515)
29. Tilghman RC, Finland M. Clinical significance of bacteremia in pneumococcal pneumonia. Arch Intern Med. 1937;59:602-619.
30. Tyrrell GJ, Lovgren M, Chui N, Minion J, Garg S, Kellner JD, Marrie TJ. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent conjugate vaccine introduction in Alberta, Canada 2000-2006. Vaccine. 2009;27:3553-3560.
31. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161:1837-1842. (Pubitemid 32762726)
32. Weinberger DM, Harboe ZB, Sanders EAM, Ndiritu M, Klugman KP, Ruckinger S, Dagan R, Adegbola R, Cutts F, Johnson HL, O'Brien KL, Scott JA, Lipsitch M. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infec Dis. 2010;51:692-699.
33. Werno AM, Murdoch DR. Laboratory diagnosis of invasive pneumococcal disease. Clin Infect Dis. 2008;46:926-932. (Pubitemid 351417200)
34. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schushat A, for the Active Bacterial Core Surveillance of the Emerging Infections Network. Decline in invasive pneumococcal disease after introduction of a protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746. (Pubitemid 36514704)
35. Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid MB, Andremont A, Klugman KP; International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotic administered and clinical outcome. Clin Infect Dis. 2003;37:230-237. (Pubitemid 36930354)